Brief: BridgeBio Reports Positive Phase 3 Topline Results For Encaleret In Patients With Autosomal Dominant Hypocalcemia Type 1
29/10/2025 11:05
Oct 29 (Reuters) - BridgeBio Pharma Inc BBIO.O: BRIDGEBIO REPORTS POSITIVE PHASE 3 TOPLINE RESULTS FOR ENCALERET IN PATIENTS WITH AUTOSOMAL DOMINANT HYPOCALCEMIA TYPE 1 BRIDGEBIO PHARMA INC: CALIBRATE STUDY OF ENCALERET FOR PATIENTS WITH ADH1 MET ALL PRE-SPECIFIED PRIMARY AND KEY SECONDARY EFFICACY ENDPOINTS BRIDGEBIO PHARMA INC: PLANS TO INITIATE REGISTRATIONAL STUDIES OF ENCALERET IN CHRONIC HYPOPARATHYROIDISM AND PEDIATRIC ADH1 IN 2026 BRIDGEBIO PHARMA INC: ENCALERET WAS WELL-TOLERATED WITH NO DISCONTINUATIONS RELATED TO STUDY DRUG BRIDGEBIO PHARMA INC - 76% OF ENCALERET PARTICIPANTS ACHIEVED TARGET CALCIUM LEVELS BRIDGEBIO PHARMA INC - 91% OF ENCALERET PARTICIPANTS ACHIEVED INTACT PTH ABOVE REFERENCE RANGE BRIDGEBIO PHARMA INC - NDA SUBMISSION PLANNED IN FIRST HALF OF 2026 Source text: ID:nGNX46kScS Further company coverage: BBIO.O
Recent news on BridgeBio Pharma
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
BridgeBio rises on FDA priority review for dwarfism drug
Brief: Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia
Brief: Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels